The Goldman Sachs Group Cuts Definitive Healthcare (NASDAQ:DH) Price Target to $3.00

Definitive Healthcare (NASDAQ:DH) had its target price decreased by The Goldman Sachs Group from $4.50 to $3.00 in a research note issued to investors on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the stock.

DH has been the topic of several other reports. Barclays lowered their price target on Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating on the stock in a research report on Monday. Stephens initiated coverage on Definitive Healthcare in a research report on Friday, December 20th. They set an “equal weight” rating and a $5.00 price target on the stock. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Definitive Healthcare in a research report on Thursday, January 16th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, Definitive Healthcare has an average rating of “Hold” and a consensus price target of $5.35.

Definitive Healthcare Stock Down 5.1 %

DH opened at $2.63 on Tuesday. Definitive Healthcare has a 12 month low of $2.58 and a 12 month high of $8.71. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49. The stock has a market cap of $303.83 million, a P/E ratio of -0.85, a P/E/G ratio of 4.06 and a beta of 1.45. The stock’s 50 day moving average price is $4.52 and its 200 day moving average price is $4.44.

Definitive Healthcare (NASDAQ:DH) last posted its earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.04). Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. The business had revenue of $62.29 million during the quarter, compared to analyst estimates of $60.60 million. As a group, research analysts predict that Definitive Healthcare will post 0.16 earnings per share for the current year.

Hedge Funds Weigh In On Definitive Healthcare

Hedge funds have recently modified their holdings of the stock. Western Wealth Management LLC acquired a new stake in shares of Definitive Healthcare in the fourth quarter worth $90,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Definitive Healthcare by 6.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 81,358 shares of the company’s stock worth $334,000 after buying an additional 4,748 shares during the period. Sone Capital Management LLC acquired a new stake in shares of Definitive Healthcare in the fourth quarter worth $953,000. Two Sigma Advisers LP boosted its position in shares of Definitive Healthcare by 1,301.5% in the fourth quarter. Two Sigma Advisers LP now owns 189,200 shares of the company’s stock worth $778,000 after buying an additional 175,700 shares during the period. Finally, Two Sigma Investments LP boosted its position in shares of Definitive Healthcare by 2,383.1% in the fourth quarter. Two Sigma Investments LP now owns 285,555 shares of the company’s stock worth $1,174,000 after buying an additional 274,055 shares during the period. 98.67% of the stock is currently owned by institutional investors and hedge funds.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.